$ENTX Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
Read the Full News Release 👉 globenewswire.com/news-release/2…
$PYPD Q4 Investor Call is happening today.
What a year it has been and more is coming.
See our PR to learn more about timing of FDA submission, new branding and new technology platform:
investors.polypid.com/news-releases/…
$ENTX We’re pleased to see Entera Bio featured in Citeline Pink Sheet’s coverage of the FDA’s qualification of total hip bone mineral density as a validated surrogate endpoint for osteoporosis drug development.
insights.citeline.com/pink-sheet/pat… (Authored by Sue Sutter)
$NSRX Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Read the full press release here: globenewswire.com/news-release/2…
Congratulations to Duke Robotics (OTCQB: DUKR) which recently announced a $750,000 Private Placement at a Premium to Market
The Company intends to use the net proceeds from the private placement for working capital, and general corporate purposes, including supporting ongoing operational and commercialization initiatives the Company is pursuing.
Duke Robotics develops advanced stabilization and autonomous robotic drone systems for both civilian and defense markets. The Company’s Insulator Cleaning Drone (IC Drone) is a first-of-its-kind, drone-enabled system for cleaning and monitoring high-voltage electric utility insulators. Leveraging Duke’s technologies, the IC Drone provides a safer, more efficient, and cost-effective alternative method. In defense, through a collaboration agreement with Elbit the Bird of Prey weapons drone system is an agile, fully stabilized remote weapon system designed for non-line-of-sight and stand-off engagements, marketed by Elbit under the brand name Bird of Prey
Read more: lnkd.in/dSCNBxwi
Today is the time the Tel Aviv Stock Exchange (@TASE_IL) will be open on a Sunday.
Staring 2026, it will shift to trading Monday-Friday, instead of Sunday-Thursday, as one of the measures to make it more attractive and aligned for the international investment community.
I analyzed 22 years of stock market data over the holidays.
The Santa Claus Rally isn't a myth. It's a 72.7% win rate.
The setup is simple: last 5 trading days of December, first 2 of January. Seven days total. Since 2003, the S&P 500 has been positive in 16 of 22 years,
Arx was pleased to support Silexion Therapeutics in its efforts to maintain its Nasdaq listing. After raising $6M, completing a reverse split and navigating the nasdaq hearing processes, Silexion has recently announced that it has regained compliance with Nasdaq's minimum bid and shareholders equity requirements.
Read more: globenewswire.com/news-release/2…
$NSRX - Laidlaw analyst Yale Jen has initiated coverage of Nasus with a Buy rating and a $22 12-month price target.
This reflects Laidlaw’s analysis as of the date of the report and is not an endorsement of it
Congratulations to our client DarioHealth, on their recent announcement of new financing of $17.5M via a private placement priced at-the-market under nasdaq rules.
DarioHealth is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. The company's ai powered platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Read more: prnewswire.com/news-releases/…
Arx founders @yehudaleibler and @rotemgantz were featured in this year’s Business Leaders Special by Yedioth Ahronoth - an annual magazine spotlighting Israel’s top business leaders, published in honor of the Jewish New Year (Rosh Hashana).
In an exclusive interview, they shared how Arx is becoming the “operating system” for publicly traded companies - helping them gain true observabity into their stock while optimizing and streamlining their investor relations.
📈✨ We’re proud to see our founders’ vision and the dedication of the entire Arx team recognized in such an influential publication as we head into another year of growth and innovation.
ynet.co.il/economy/rememb…
Should publicly traded companies in the US be allowed to report earnings just twice a year, instead of quarterly?
In an article for @Investingcom I wrote about this not-so-new debate which @realDonaldTrump just reignited: investing.com/analysis/from-…
Other markets have already tested it - from the UK and EU to Israel and Japan. The outcome have been mixed: reduced compliance burdens for some issuers, but also thinner analyst coverage, more volatility, and little evidence of greater long-term investment.
This is not a one-size-fits-all question. For early-stage, R&D focused cash-burning firms, lighter updates could free focus and resources. For large-caps and index constituents, steady quarterly detail remains essential for trust, comparability, and liquidity. Exchanges and institutional investors can also play a role in setting disclosure standards, as Germany’s tiered approach has shown.
Markets thrive on trust, and trust thrives on information. The SEC’s challenge is not whether to abandon quarterlies altogether, but how to recalibrate them - scaling back where the burden is greatest, while preserving transparency where the stakes are highest.
What happens when a single Trump post questions the entire U.S. quarterly reporting system?
@YehudaLeibler breaks down why this debate matters, what other markets have tried, and how the SEC could rewrite the rules of disclosure. Could semiannual reporting really save costs - or just leave investors flying blind?
Read the full column on @Investingcom: investing.com/analysis/from-…
8 Followers 4 FollowingOn a mission to make every prescription safer. AI-powered clinical decision support protecting patients & reducing drug-related harm globally. $SEGN.V (TSXV)
12K Followers 12K FollowingCEO/Founder AlphaForgeUSA & InvestorConnectAI | Former Marine | Building AI agents that find alpha. | Meet my AI agent → @alpha_forge_ai 🤖
11K Followers 8K FollowingAuthor of: Amida - The Final Prophecy (to be released next month.) An orthodox Jewish baal teshuvah zionist settler that hates labels.
4K Followers 33 FollowingPurple Biotech (NASDAQ/TASE: PPBT) is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion & drug resistance
21 Followers 2 FollowingNasus pharma develops powder-based Intranasal specialized product portfolio, to address acute medical conditions and public health threats. NYSE: $NSRX
303 Followers 85 FollowingExploring emerging innovators.
#NFA. Part of WallStWire distribution net. Disclaimers: https://t.co/9cXUp5AZM4. Posts re subscribers marked #WallStWire
104 Followers 101 FollowingSilexion Theraputics is a Clinical-stage company developing proprietary treatments for KRAS-driven cancers. NASDAQ: $SLXN (Prv. $MACA)
34 Followers 28 FollowingDuke Robotics is a forward-thinking company focused on bringing advanced stabilization & autonomous solutions to military and civilian sectors. NASDAQ: $DUKR
1K Followers 57 FollowingInnocan is a #pharma #tech company that focuses on the development of disruptive, science-driven #CBD delivery platforms and products $INNO $INNPF $IP4
8 Followers 4 FollowingOn a mission to make every prescription safer. AI-powered clinical decision support protecting patients & reducing drug-related harm globally. $SEGN.V (TSXV)
4K Followers 33 FollowingPurple Biotech (NASDAQ/TASE: PPBT) is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion & drug resistance
29 Followers 1 FollowingMediWound Ltd. is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. | Nasdaq: $MDWD
34 Followers 28 FollowingDuke Robotics is a forward-thinking company focused on bringing advanced stabilization & autonomous solutions to military and civilian sectors. NASDAQ: $DUKR
21 Followers 2 FollowingNasus pharma develops powder-based Intranasal specialized product portfolio, to address acute medical conditions and public health threats. NYSE: $NSRX
104 Followers 101 FollowingSilexion Theraputics is a Clinical-stage company developing proprietary treatments for KRAS-driven cancers. NASDAQ: $SLXN (Prv. $MACA)
54K Followers 5K FollowingI write about venture capital & the circles that run Silicon Valley for Bloomberg @technology. Find me on Signal at +1 925 271 0912.
18K Followers 1K FollowingCEO at @JoinBelong. Anyone can own a rental Home. Backed by @a16z, @notablecap @BatteryVentures.🇦🇷 Born. Prev EIR @A16Z. Steak is a strict discipline.
1K Followers 97 FollowingWorking on something new. AI, visuals - check out https://t.co/qNuzdX43ot
Builder of viral startups & products for +20 years @ZUtALabs @Umooveme https://t.co/zrwBt0GQev & much more.
311K Followers 7K FollowingFounder and CEO of @acquiredotcom. https://t.co/wRMIssDmhl has helped 1000s of startups get acquired and facilitated $500m+ in closed deals.
217 Followers 126 FollowingCrypto investor & builder. Co-founded Linen Wallet, LoanScan. Now building @ArikamiHQ — an investment research system for deliberate crypto investors.